As part of a preliminary review, FDA determined that the application was not sufficient enough for a substantive review.
The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix's treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy, the company said.Zogenix's drug uses a low-dose, liquid solution of fenfluramine, which was used in an obesity drug combination, which is now off the market. The treatment was pulled off the market due to evidence of heart valve damage.
The FDA cited a lack of certain non-clinical studies to assess the chronic administration of fenfluramine and due to an incorrect dataset. Zogenix will have to resubmit its marketing application before any future launch after the FDA's"Refusal to File" letter. Current treatment options for Dravet syndrome, which affects an estimated 20,000 patients in the United States, are limited to a combination of seizure medication and drugs to prevent emergencies.
Shares of GW Pharmaceuticals, which last July gained approval for its cannabis-based drug to treat the disease, were up 4 percent at $174.30 after the bell.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Zogenix stock drops 25% after FDA rejects filingZogenix Inc. shares dropped in the extended session Monday after announcing that the Food and Drug Administration did not accept a marketing application for...
और पढो »
FDA investigating possible seizure risk with e-cigarette useThe FDA said it is investigating reports of e-cigarette users experiencing seizures. There have been a small number of cases over several years.
और पढो »
Blood pressure patients can take tainted pills during valsartan shortage, FDA saysDue to a shortage of certain commonly used blood pressure drugs, the FDA took the unusual step of reminding patients that they have access to available -- if tainted -- medicines while a fresh supply of uncontaminated pills is manufactured.
और पढो »
Vaping may cause seizures, especially among teens, FDA says“We have reports indicating that some people who use e-cigarettes, especially youth and young adults, are experiencing seizures following their use,” FDA commissioner says in a statement. - TODAYshow
और पढो »
FDA sends letters to 20 companies in attempt to rein in stem cell industryThe enforcment action comes after years of scientists’ demands for agency to do more.
और पढो »
FDA, FTC send warning letters to three CBD marketers for false medical claimsThe FDA and the FTC sent warning letters to 3 companies that market cannabidiol products, saying the companies are making false claims about treating diseases such as cancer and Alzheimer's.
और पढो »
FDA is investigating nearly three dozen reports of seizures after vapingBetween 2010 and 2019, the FDA received 35 reports of people having seizures after using e-cigarettes. The cause of the seizures is unclear.
और पढो »
FDA investigates reports of seizures after vapingThe US Food and Drug Administration announced Wednesday it is investigating a possible connection between e-cigarette use and seizures in younger users.
और पढो »
Outgoing FDA chief Gottlieb raises 'concern' over Walgreens, CVS selling CBD productsOutgoing Food and Drug Administration Commissioner Scott Gottlieb told lawmakers Wednesday that he's uneasy about Walgreens' and CVS' recent decisions to start selling CBD products in their drugstores.
और पढो »